目的 探討孟魯司特鈉聯(lián)合布地奈德治療咳嗽變異性哮喘的臨床療效。方法 選取2014年7月—2016年11月鄭州大學(xué)第五附屬醫(yī)院收治的咳嗽變異性哮喘患者78例，按照序列號(hào)法分為對(duì)照組（38例）和治療組（40例）。對(duì)照組吸入布地奈德氣霧劑，200 μg/次，2次/d。治療在對(duì)照組的基礎(chǔ)上口服孟魯司特鈉片，10 mg/次，1次/d。兩組患者均連續(xù)治療8周。觀察兩組的臨床療效，比較兩組的肺功能和炎癥反應(yīng)情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為73.68%、92.50%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組最大通氣量（MVV）、1秒用力呼氣容積（FEV1）、FEV1/用力肺活量（FVC）和最大呼氣流量（PEF）均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些觀察指標(biāo)的升高程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組白細(xì)胞介素-6（IL-6）、腫瘤壞死因子α（TNF-α）、白細(xì)胞介素-4（IL-4）、白細(xì)胞介素-5（IL-5）和白細(xì)胞介素-13（IL-13）水平均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。結(jié)論 孟魯司特鈉聯(lián)合布地奈德治療咳嗽變異性哮喘具有較好的臨床療效，可改善肺功能，減輕炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of montelukast combined with budesonide in treatment of cough variant asthma. Methods Patients (78 cases) with cough variant asthma in the Fifth Affiliated Hospital of Zhengzhou University from July 2014 to November 2016 were randomly divided into control group (38 cases) and treatment group (42 cases). Patients in the control group were inhalation administered with Budesonide Aerosol, 200 μg/time, twice daily. Patients in the treatment group were po administered with Montelukast Sodium Tablets on the basis of the control group, 10 mg/time, once daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and pulmonary function and inflammatory reaction in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.68% and 92.50%, respectively, and there was difference between two groups (P < 0.05). After treatment, MVV, FEV1, FEV1/FVC, and PEF in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of IL-6, TNF-α, IL-4, IL-5, and IL-13 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Montelukast combined with budesonide in treatment of cough variant asthma, can improve pulmonary function, and relieve inflammatory reaction, which has a certain application value.